CYP1B1 and prostate carcinoma: CYP1B1 inhibitors have also been shown to enhance the chemotherapeutic effects of DOX in several cancer cell lines including lung cancer [192–194], breast cancer [195–201], liver cancer [201–204], glioblastoma [205], prostate cancer [206], colorectal cancer [207,208], gastric cancer [209], and leukemia [210,211].